Cardiff Oncology shares plunge after Q2 earnings miss
Y-mAbs Therapeutics, Inc. (YMAB) stock has reached a new 52-week low, dipping to $4.23, as the company faces a tumultuous period in the biopharmaceutical market. According to InvestingPro data, despite the company's "GOOD" overall financial health score, the stock has declined over 67% in the past six months. Notably, YMAB maintains a strong liquidity position with a current ratio of 4.16x. This latest price point reflects a significant downturn from previous valuations, with the stock experiencing a stark 1-year change with a decline of -69.48%. While the company generated $87.7 million in revenue over the last twelve months, analysts have recently revised their earnings expectations downward. Investors are closely monitoring YMAB's performance and strategic decisions as the company navigates through the challenges that have led to this notable decrease in stock value. For deeper insights into YMAB's valuation and growth prospects, access the comprehensive Pro Research Report available on InvestingPro, which covers over 1,400 US stocks with expert analysis and actionable intelligence.
In other recent news, Y-mAbs Therapeutics reported its fiscal year 2024 revenue at $87.7 million, aligning with market expectations. However, the company provided a 2025 revenue guidance of $75 million to $90 million, which fell short of analysts' earlier projections. In response, several firms adjusted their price targets for Y-mAbs. Jones Trading lowered its target to $18 while maintaining a Buy rating, citing the company's long-term potential and confidence in its pipeline. Meanwhile, Morgan Stanley (NYSE:MS) reduced its target to $7 and maintained an Underweight rating, pointing to challenges faced by the product Danyelza in the market.
Cantor Fitzgerald also adjusted its price target to $19, maintaining an Overweight rating, and noted potential growth opportunities for Danyelza in future years. BofA Securities decreased its target to $12, retaining a Neutral rating, as it acknowledged the company's strategic realignment efforts. Additionally, Y-mAbs announced an Equity Distribution Agreement with Oppenheimer & Co. Inc., allowing for potential stock offerings up to $35 million. This agreement provides the company with flexibility in financing its operations as needed.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.